broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K57080016-001-15-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.494768 | -0.229827 | 0.041726 | 0.785715 | 0.018052 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000906 |
BRD-K57169635-001-04-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.630623 | 0.674623 | 0.108177 | 0.893097 | 0.756705 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000906 |
BRD-K58435339-001-03-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.342023 | 0.506329 | 0.196793 | 0.632366 | 0.039616 | 0.38558 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000906 |
BRD-K62200014-003-10-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.602878 | 0.406675 | -0.092569 | 0.728064 | 0.006683 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000906 |
BRD-K62391742-001-09-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.476345 | -0.086451 | -0.106384 | 0.766757 | 0.005962 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000906 |
BRD-K63504947-001-14-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.744131 | -4.645308 | 0.121427 | 0.890273 | 0.039152 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000906 |
BRD-K64052750-001-22-5 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.054549 | -0.643843 | 0.016985 | 1 | 0.053393 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000906 |
BRD-K64881305-001-03-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.154767 | 3.124389 | 0.599917 | 0.575811 | 0.076705 | 0.08636 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000906 |
BRD-K69001009-001-02-8 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.653848 | 0.013312 | -0.031028 | 0.825649 | 0.025815 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000906 |
BRD-K69694239-001-02-2 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.636577 | 4.192894 | 0.209536 | 0.884609 | 0.458979 | null | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000906 |
BRD-K76210423-001-01-6 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.736278 | -0.140291 | -0.007005 | 0.841801 | 1.561675 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000906 |
BRD-K76908866-001-07-6 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.809977 | 1.617852 | -0.114616 | 0.923282 | 0.199007 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000906 |
BRD-K77625799-001-07-7 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.643497 | -0.671027 | -0.102113 | 0.875889 | 0.015529 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000906 |
BRD-K81418486-001-44-2 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.036634 | 1.968034 | 0.562936 | 0.816126 | 1.590004 | 1.652676 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000906 |
BRD-K85402309-043-01-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.620964 | -0.023804 | -0.022992 | 0.813776 | 0.009054 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000906 |
BRD-K86118762-001-01-8 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.888402 | -7.171739 | -0.012965 | 0.91951 | 0.668567 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000906 |
BRD-K87737963-001-06-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.312552 | -0.685352 | 0.07298 | 0.947051 | 0.00034 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000906 |
BRD-K87782578-001-01-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.405707 | 2.384415 | 0.538032 | 0.904739 | 2.13273 | 4.293188 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000906 |
BRD-K87909389-003-03-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.408271 | 3.46073 | 0.663776 | 0.773785 | 0.103959 | 0.169696 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000906 |
BRD-K96123349-236-02-8 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.0805 | -0.090005 | -0.125098 | 1 | 46.352979 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000906 |
BRD-K98572433-001-02-9 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 1.388821 | 0.666644 | 0.03142 | 1 | 0.058889 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000906 |
BRD-K99113996-001-02-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.629899 | 1.227008 | 0.136391 | 0.877139 | 0.405138 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000906 |
BRD-K99749624-001-07-0 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.662855 | 0.700928 | -0.059945 | 0.854541 | 0.159347 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000906 |
BRD-M97302542-001-04-4 | ACH-000906 | ES2_OVARY | MTS010 | 1 | 0.753715 | -0.94634 | 0.168282 | 0.924948 | 0.011006 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000906 |
BRD-A25234499-001-19-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.175878 | -0.702884 | -0.013093 | 1 | 0.069353 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000909 |
BRD-A74914197-001-02-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.259312 | 4.071128 | 0.865844 | 0.603622 | 0.003469 | 0.004152 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000909 |
BRD-K02113016-001-19-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.00593 | 0.79508 | 0.7318 | 0.74902 | 1.042762 | 1.058533 | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000909 |
BRD-K02130563-001-11-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.097285 | 0.280018 | 0.464705 | 0.415621 | 0.006522 | 0.014124 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000909 |
BRD-K03390685-001-01-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.569215 | 0.483312 | 0.076498 | 0.919708 | 4.781759 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000909 |
BRD-K03406345-001-21-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.820971 | -2.971623 | 0.188074 | 0.904567 | 0.107648 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000909 |
BRD-K03449891-001-08-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.106386 | 8.355424 | 0.736934 | 0.737482 | 0.577897 | 0.594688 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000909 |
BRD-K03765900-001-01-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.62038 | 0.039339 | -0.000961 | 0.81477 | 0.267409 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000909 |
BRD-K05804044-001-18-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.476623 | 3.708865 | 0.447965 | 0.796932 | 0.231595 | 0.528904 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000909 |
BRD-K06814349-304-02-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.587737 | 0.258398 | -0.03465 | 0.855245 | 1.128093 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000909 |
BRD-K08109215-001-06-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.139643 | 2.344615 | 0.269324 | 1 | 0.010809 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000909 |
BRD-K08542803-001-02-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.172445 | 6.956439 | 0.909231 | 0.691165 | 0.267381 | 0.284142 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000909 |
BRD-K08547377-001-04-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.211132 | 3.44147 | 0.741696 | 0.453672 | 0.012054 | 0.014138 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000909 |
BRD-K08703257-001-13-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.033167 | -0.278712 | -0.027861 | 1 | 0.076153 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000909 |
BRD-K08799216-001-05-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.200008 | -0.301173 | -0.019643 | 1 | 0.015813 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000909 |
BRD-K09951645-001-11-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.079899 | 0.072724 | 0.00111 | 1 | 0.000024 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000909 |
BRD-K11267252-001-05-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.992122 | 0.234345 | -0.070175 | 0.997903 | 8.994083 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000909 |
BRD-K11630072-001-13-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.174481 | 7.99295 | 0.597818 | 0.857087 | 1.863642 | 1.966469 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000909 |
BRD-K12184916-001-19-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.343782 | 1.152949 | 0.414399 | 0.452491 | 0.002557 | 0.007015 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000909 |
BRD-K12343256-001-14-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.961553 | -0.114585 | -0.145694 | 0.974648 | 28.74868 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000909 |
BRD-K13049116-001-04-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.208821 | 4.085603 | 0.655692 | 0.837838 | 1.368316 | 1.56192 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000909 |
BRD-K13390322-001-06-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.137096 | 2.988273 | 0.919962 | 0.678617 | 0.269323 | 0.299815 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000909 |
BRD-K13662825-001-07-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.156051 | 14.633779 | 0.900588 | 0.457362 | 0.004886 | 0.005012 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000909 |
BRD-K14109347-001-03-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.8691 | 0.369099 | -0.046749 | 0.962486 | 1.655405 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000909 |
BRD-K15179879-001-03-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.195582 | 1.623181 | 0.48137 | 0.30301 | 0.002058 | 0.002793 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000909 |
BRD-K15600710-066-05-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.107248 | 7.457046 | 0.879948 | 0.691666 | 0.343882 | 0.355198 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000909 |
BRD-K16730910-001-10-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.246517 | 0.736027 | 0.655865 | 0.789617 | 0.80555 | 2.027315 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000909 |
BRD-K17555800-003-02-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.747187 | 0.523218 | 0.044777 | 0.87575 | 0.086056 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000909 |
BRD-K17610631-001-03-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.160719 | 3.025032 | 0.68718 | 0.658249 | 0.186194 | 0.211659 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000909 |
BRD-K17743125-001-08-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -0.076811 | 0.329259 | 0.285354 | 0.706714 | 2.705077 | 1.752606 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000909 |
BRD-K17894950-001-14-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.407415 | -0.368298 | 0.279635 | 1 | 0.011732 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000909 |
BRD-K18961567-001-01-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.071496 | 1.325664 | 0.583804 | 0.879125 | 3.305835 | 3.713929 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000909 |
BRD-K19540840-001-09-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.426253 | 0.440327 | 0.179605 | 1 | 0.022083 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000909 |
BRD-K19687926-001-04-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.730655 | -1.11136 | 0.035731 | 0.941148 | 0.00465 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000909 |
BRD-K19796430-001-05-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.270104 | 1.960147 | -0.094732 | 1 | 0.443045 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000909 |
BRD-K22064724-001-01-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.084521 | 7.901051 | 0.715773 | 0.620713 | 0.179408 | 0.183663 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000909 |
BRD-K22822991-001-02-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.697145 | 0.919375 | 0.040918 | 0.819646 | 0.030163 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000909 |
BRD-K23228615-001-02-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.127999 | 1.389138 | 0.805844 | 0.720972 | 0.452423 | 0.559756 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000909 |
BRD-K23984367-001-07-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.212663 | 1.845122 | 0.559266 | 0.878718 | 2.323733 | 3.137356 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000909 |
BRD-K26026438-001-01-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.620155 | -0.910446 | 0.101812 | 0.970889 | 0.000589 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000909 |
BRD-K26657438-001-15-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.978362 | -0.063499 | 0.000602 | 0.990234 | 0.003518 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000909 |
BRD-K28822270-001-03-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.592743 | 2.527207 | 0.393969 | 0.689016 | 0.006327 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000909 |
BRD-K29905972-001-06-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.233607 | 1.606141 | 0.583946 | 0.745759 | 0.401206 | 0.593771 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000909 |
BRD-K30577245-001-05-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.229961 | 4.978455 | 0.588882 | 0.531163 | 0.001697 | 0.00192 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000909 |
BRD-K31698212-001-02-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.175842 | 0.099534 | -0.024194 | 1 | 1.782986 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000909 |
BRD-K31928526-001-02-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.240141 | 1.943205 | 0.668781 | 0.659615 | 0.129434 | 0.181266 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000909 |
BRD-K33379087-001-07-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.475498 | 2.741417 | 0.59106 | 0.790251 | 0.206326 | 0.619904 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000909 |
BRD-K33610132-001-02-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.476749 | 3.528809 | 0.488546 | 0.891163 | 1.328742 | 3.169981 | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000909 |
BRD-K33622447-066-01-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.255078 | 3.053717 | 0.276505 | 0.933602 | 4.313609 | 5.449263 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000909 |
BRD-K35520305-001-16-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.218148 | -0.018957 | -0.004364 | 1 | 0.031175 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000909 |
BRD-K36627727-001-05-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.893594 | 2.597519 | -0.082152 | 0.965776 | 0.44104 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000909 |
BRD-K36788280-001-01-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.772813 | -3.693743 | 0.111191 | 0.843762 | 0.482836 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000909 |
BRD-K37379014-001-02-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.642337 | 0.068339 | -0.084226 | 0.824192 | 0.002008 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000909 |
BRD-K38332599-001-01-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.124478 | 0.663084 | 0.499958 | 0.664287 | 0.268807 | 0.413943 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000909 |
BRD-K38527262-300-01-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -0.029297 | 1.33343 | 0.513521 | 0.882979 | 3.714043 | 3.55878 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000909 |
BRD-K38852836-001-02-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.161338 | 5.375585 | 0.670603 | 0.729517 | 0.109419 | 0.117644 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000909 |
BRD-K39974922-001-04-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.584306 | 5.424289 | 0.435812 | 0.919842 | 1.539178 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000909 |
BRD-K41859756-001-06-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.121437 | 3.850259 | 0.813088 | 0.590233 | 0.027093 | 0.029123 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000909 |
BRD-K42495768-001-01-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.15696 | 1.28707 | 0.569296 | 0.893467 | 3.510448 | 4.70427 | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000909 |
BRD-K42805893-001-04-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.258441 | 0.003565 | -0.022068 | 1 | 0.021053 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000909 |
BRD-K42828737-001-03-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -1.35453 | 3.688715 | 0.286187 | 0.981548 | 13.575104 | 9.51519 | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000909 |
BRD-K42898655-001-01-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.52989 | 0.301944 | 0.199987 | 0.782788 | 0.017259 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000909 |
BRD-K43389675-001-02-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.093333 | 0.704202 | 0.908513 | 0.354956 | 0.008201 | 0.010997 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000909 |
BRD-K44227013-001-06-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.23222 | 1.319856 | 0.539212 | 0.649874 | 0.119856 | 0.192366 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000909 |
BRD-K44408410-001-17-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.240545 | 2.46541 | 0.295254 | 0.936091 | 4.683573 | 6.111378 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000909 |
BRD-K46386702-001-02-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.899927 | 0.012752 | -0.01258 | 0.956811 | 188,632,592.543129 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000909 |
BRD-K49328571-001-15-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 3.857633 | 0.577667 | 0.646773 | 1 | 0.889557 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000909 |
BRD-K50010139-001-01-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.197876 | -0.817601 | 0.091765 | 1 | 0.192077 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000909 |
BRD-K50168500-001-07-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.960175 | -1.121231 | 0.002362 | 0.971663 | 0.63286 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000909 |
BRD-K51791723-003-01-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.258033 | 4.541767 | 0.687407 | 0.712693 | 0.233336 | 0.273771 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000909 |
BRD-K51967704-001-03-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.110478 | 9.924652 | 0.564066 | 0.817533 | 1.365995 | 1.400803 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000909 |
BRD-K52313696-001-12-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.589983 | 0.172671 | -0.12818 | 0.74328 | 0.003331 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000909 |
BRD-K53414658-001-08-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -0.000054 | 1.083979 | 0.702371 | 0.825304 | 2.153562 | 2.153347 | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000909 |
BRD-K53972329-001-07-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.192842 | 0.024698 | -0.000979 | 1 | 0.003962 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000909 |
BRD-K54256913-001-08-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.151841 | -0.112437 | -0.000012 | 1 | 0.003754 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000909 |
BRD-K54955827-001-02-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.183348 | 1.097292 | 0.899888 | 0.709075 | 0.321481 | 0.487478 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000909 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.